Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients by Jeffrey F Barletta & David A Sclar
Barletta and Sclar Critical Care  (2014) 18:714 
DOI 10.1186/s13054-014-0714-7RESEARCH Open AccessProton pump inhibitors increase the risk for
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Jeffrey F Barletta* and David A SclarAbstract
Introduction: Proton pump inhibitors (PPI) have been linked to Clostridium difficile infection (CDI) but there are few
data specific to ICU patients. We evaluated duration of PPI exposure as a potential risk factor for hospital-acquired
CDI in the ICU.
Methods: This retrospective, case-control study was conducted using the Multiparameter Intelligent Monitoring in
Intensive Care II database, a large publically available database of more than 35,000 ICU patients. Adult patients with
CDI were identified using the ICD-9 code for Clostridium difficile listed as a secondary diagnosis. To be included,
patients had to be present in an ICU for ≥48 hours prior to Clostridium difficile acquisition. These patients were
then matched to patients without CDI using the ICD-9 primary diagnosis, age (+/−5 years) and SOFA score (+/−1).
Successfully matched patients were reviewed for PPI exposure and other potential confounding variables for CDI.
PPI exposure was characterized as short (<2 days) or long (≥2 days). Multivariate modeling was performed to
identify independent risk factors for CDI.
Results: There were 408 patients evaluated and 81% received a PPI. The percentage of patients who had a long
exposure to PPIs was 83% in the CDI group compared to 73% with controls (P = 0.012). Upon inclusion of the
following variables into a multivariate analysis (long PPI exposure, histamine-2-receptor antagonist administration,
antibiotic administration, immunosuppression and study duration), long PPI exposure (odds ratio (OR) (95%
confidence interval (CI) = 2.03 (1.23 to 3.36), P = 0.006) and antibiotic use (OR (95% CI) = 2.52 (1.23 to 5.18), P = 0.012)
were identified as independent predictors of CDI.
Conclusions: Proton pump inhibitors are independent risk factors for the development of CDI in ICU patients. This
risk is particularly exposed after two or more days of therapy.Introduction
Clostridium difficile infection (CDI) is the leading cause
of hospital-associated infectious diarrhea with consider-
able impact on length of stay and costs [1]. The preva-
lence of CDI in mechanically ventilated, intensive care
unit (ICU) patients is 6.6% with most cases (69%) being
diagnosed during the ICU admission [2]. The high fre-
quency of CDI in critically ill patients is particularly con-
cerning given the multiple risk factors that are present
and the increased risk for adverse outcomes in this
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unless otherwise stated.Recently, proton pump inhibitors (PPIs) have been
widely implicated as a significant risk factor for hospital-
acquired CDI [3-9]. In one large database study of ICU
patients, the odds ratio (OR) for CDI was significantly
greater with PPI use compared to histamine-2-receptor
antagonists (H2RA) (OR (95% confidence interval (CI) =
1.29 (1.04 to 1.64)). Infection-related risks with PPIs are
believed to be greatest shortly after starting therapy
[3,10-12]. One study evaluating the relationship between
duration of PPI therapy and nosocomial CDI revealed a
significant increase in risk after only two days of PPI
use [3].
PPIs have become the most common modality for the
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generally short-term, even an abbreviated exposure could
lead to substantial increases in morbidity and overall hos-
pital costs. The objective of this study was to further
describe the relationship between PPI use and hospital-
acquired CDI in critically ill patients and evaluate duration
of inpatient PPI exposure as a risk factor for CDI.
Methods
This case-control study was conducted using the Multi-
parameter Intelligent Monitoring in Intensive Care II
(MIMIC II) database, version 2.6 [15,16]. This database
is a large, publically available database that encompasses
more than 35,000 patients admitted to the Beth Israel
Deaconess Medical Center from 2001 to 2008. Beth
Israel Deaconess Medical Center is a 620-bed tertiary
academic medical center in Boston, MA, USA with 77
critical care beds [16]. The MIMIC II database provides
a high-resolution record of time-stamped clinical vari-
ables, physiologic data, diagnoses and interventions that
have been de-identified in a Health Insurance Portability
and Accountability Act-compliant manner. The database
was queried in August, 2013. Institutional Review Board
approval was obtained (Midwestern University, AZ#754)
prior to study initiation. The need for informed consent
was waived.
Adult patients with CDI were first identified using the
International Classification of Diseases, Ninth Revision
(ICD-9) code for Clostridium difficile (008.45) listed as a
secondary diagnosis. To be included, patients had to
be present in an ICU for at least 48 hours prior to itsFigure 1 Patient evaluation and stratification.acquisition. These patients were then matched to patients
without CDI in a 1-to-1 ratio using the ICD-9 primary
diagnosis, Sequential Organ Failure Assessment (SOFA)
score (+/−1) and age (+/−5 years). Patients were ex-
cluded if Clostridium difficile was listed as a primary
admitting diagnosis, if a successful match could not
be obtained or if the medication record was missing or
incomplete.
All successfully matched patients meeting inclusion/
exclusion criteria were reviewed for demographics,
medication history, comorbidities and other potential
confounding variables for CDI. These included PPI ex-
posure, H2RA use, antimicrobial therapy and immuno-
suppression. To characterize inpatient PPI exposure,
two groups were formed based on the duration of PPI
therapy, <2 days (short) or ≥2 days (long). These groups
were formed based on previous research demonstrating
an increase in risk for hospital-acquired CDI when dur-
ation approaches two days [3]. Classification and regression
tree analysis was performed to confirm this cutoff. Anti-
biotic use was coded as yes if more than one dose of a
systemic antibiotic was received. All drug exposures (PPI,
H2RA, antibiotics) and durations of therapy were censored
to the acquisition of CDI if applicable. Immunosuppression
consisted of patients who received immunosuppressant
drug therapy (for organ transplantation, lupus, HIV or
arthritis), receipt of >10 mg prednisone equivalence or
those with malignancy receiving chemotherapy. Study dur-
ation included the time from hospital admission to the
acquisition of CDI (for CDI patients) or until hospital
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Venous thromboembolism 1% (6)
Miscellaneous 3% (14)
SOFA 6 (0 – 18)
Mechanical ventilation 73% (296)
Immunosuppression 30% (121)
Long PPI exposure (2 or more days) 78% (319)
PPI duration (days) 7 (0 – 96)
H2RA use 34% (138)
Long H2RA exposure (2 or more days) 28% (116)
H2RA duration (days) 0 (0 – 62)
Antibiotic use 90% (368)
Total number of antibiotics received 2 (0 – 8)
Study duration (days) 10 (2 – 99)
Data are presented as mean ± standard deviation, median (range) or % (n).
ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; PPI,
proton pump inhibitor; H2RA, histamine-2-receptor antagonist.
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patients were stratified into two groups based on the
dichotomous presence of CDI. Confounding variables
were compared between groups using univariate statis-
tics. Student’s t test was used for continuous data that
were normally distributed while Mann-Whitney U test
was used for data that were skewed. Pearson’s chi-square
or Fisher’s exact test were used as appropriate for dichot-
omous variables. Multivariate modeling was performed
using conditional logistic regression with a backwards
stepwise elimination procedure. Variables for inclusion
into the model were selected using the results from the
univariate analysis (that is, those with a P value <0.1)
along with variables that were deemed to be clinically
relevant to the acquisition of CDI. These variables were
H2RA use, antibiotic use, immunosuppression and study
duration. A P value <0.05 was used to determine statistical
significance. IBM SPSS, version 19.0 (IBM Corp, Armonk,
NY, USA) was used for all analyses.
Results
There were 408 patients evaluated (Figure 1). The majority
of patients were mechanically ventilated (73%) and admit-
ted to either a cardiac ICU (51%) or a medical ICU (44%)
(Table 1). For patients with CDI, the time from hospital
admission to acquisition of C.difficile was 9.7 (2.4 to 56)
days while the time from ICU admission to CDI was 8.3
(2 to 56) days. A total of 81% (332) patients received a PPI.
PPI use was higher in patients who developed CDI
compared to those who did not (Table 2). Specifically
the percentage of patients who had a long exposure to
PPIs (that is, two or more days) was 83% in the CDI
group compared to 73% with controls (P = 0.012). Anti-
biotic use was also associated with CDI on univariate ana-
lysis. The relationship between CDI, PPIs and antibiotics
is displayed in Figure 2.
Upon inclusion of the following variables into a multi-
variate analysis (long PPI exposure, H2RA administra-
tion, antibiotic administration, immunosuppression and
study duration), long PPI exposure (OR (95% CI) = 2.03
(1.23 to 3.36), P = 0.006) and antibiotic use (OR (95%
CI) = 2.52 (1.23 to 5.18), P = 0.012) were identified as
independent predictors of CDI (Table 3).
Discussion
Clostridium difficile is a highly prevalent nosocomial
pathogen that represents a substantial burden to the
health care system. Critically ill patients are at great risk
for acquiring CDI given the many risk factors they are
exposed to during their hospital admission. Historically,
antibiotic use has been the primary drug-related culprit
but acid suppressive therapy is increasingly being recog-
nized as a probable cause. One study noted an increased
risk for nosocomial CDI as the intensity of acid suppressionincreased [4]. Specifically, the ORs reported (compared to
no acid suppression) were 1.53 for H2RA therapy, 1.74 for
daily PPI therapy and 2.36 for more frequent administra-
tion. A second study evaluated the risk for CDI based on
the duration of PPI therapy given most hospitalized patients
receive daily PPI therapy for SUP [3]. In this study the OR
(95% CI) for acquiring CDI was 1.14 (1.02 to 1.27) for each
day of PPI therapy. Using classification and regression tree
analysis, the risk for CDI increased when the duration of
PPI therapy exceeded one day for patients with a prior
hospital admission and two days in those without. How-
ever, only 26% of patients in this analysis were in an ICU,
therefore, the validity of this model in critically ill patients
is questionable. The current study was conducted to test
the applicability of these thresholds in ICU patients.
Table 2 Univariate analysis of confounding variables associated with Clostridium difficile
Variable C. difficile - YES (n = 204) C. difficile - NO (n = 204) P value
Age 68.6 ± 15 68.5 ± 15 0.949
Gender (% male) 55% (113) 57% (116) 0.765
ICU type 0.770
Cardiac/Cardiothoracic 51% (104) 51% (103)
Medical 43% (88) 45% (92)
Surgical 6% (12) 4% (9)
Classification of primary diagnosis 1.00
Cardiovascular 24% (49) 24% (49)
Infection 23% (46) 23% (46)
Gastrointestinal 14% (28) 14% (28)
Respiratory 12% (25) 12% (25)
Neurologic 9% (18) 9% (18)
Cancer 6% (13) 6% (13)
Trauma 5% (10) 5% (10)
Renal 2% (5) 2% (5)
Venous thromboembolism 1% (3) 1% (3)
Miscellaneous 3% (7) 3% (7)
SOFA 6 (0 – 17) 6 (0 – 18) 0.798
Mechanical ventilation 74% (151) 71% (145) 0.506
Immunosuppression 28% (56) 32% (65) 0.329
Long PPI exposure (2 or more days) 83% (170) 73% (149) 0.012
PPI duration (days) 7 (0 – 56) 6 (0 – 96) 0.488
H2RA use 32% (65) 36% (73) 0.403
Long H2RA exposure (2 or more days) 26% (53) 31% (63) 0.272
H2RA duration (days) 0 (0 – 21) 0 (0 – 62) 0.474
Antibiotic use 94% (191) 87% (177) 0.020
Total number of antibiotics received 3 (0 – 7) 2 (0 – 8) 0.001
Study duration (days) 9.7 (2.4 – 55.7) 10 (2 – 99) 0.253
Data are presented as mean ± standard deviation, median (range) or % (n). ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment; PPI, proton pump
inhibitor; H2RA, histamine-2-receptor antagonist.
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for two or more days is associated with a two-fold
increase in CDI. This is similar to data reported in non-
ICU patients and confirms the previously identified
thresholds for PPI duration and risk for CDI. Further-
more, we have revealed the risk for CDI caused by PPIs
is similar to that observed with antimicrobial therapy. In
fact, no difference in CDI incidence was noted in the co-
hort of patients who received antibiotics but had a short
duration of PPI use (<2 days) compared to those who
did not receive antibiotics but had a long duration of
PPI use. A synergistic effect, however, was not observed
when both antibiotics and long PPI therapy was provided.
This differs from a previously published meta-analysis
whereby the odds ratio for CDI was 1.97 for antibioticsalone and 1.82 for PPI alone but 3.44 when PPIs were ad-
ministered with antibiotics [6].
The short duration of PPI exposure that is associated
with CDI stimulates controversy regarding the true path-
ophysiologic mechanism of this relationship. One hypo-
thesis is that increased gastric pH levels (caused by
decreased acid secretion) facilitate the growth of patho-
genic flora in the gastrointestinal (GI) tract. In addition,
elevated gastric pH may also allow conversion from
spores to vegetative cells that ultimately produce toxin
[1]. The fact that maximal acid suppression with PPIs is
not reached for several days after starting therapy yet
the risk for infectious complications is greatest shortly
after initiation bring reservation to this theory [12,17]. An
alternative hypothesis relates to the immunomodulatory
Figure 2 The relationship between proton pump inhibitors, antibiotics and Clostridium difficile. For pair-wise comparisons, *P= 0.013; †P= 0.777;
‡P= 0.585.
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ity [18-20]. In fact, in one study neutrophil bactericidal
activity was decreased by 30% following a single dose of
omeprazole [20]. Future research is required to elucidate
the underlying mechanism.
There are few studies evaluating PPI therapy and CDI
specific to the ICU. Beaulieu et al. reviewed medical re-
cords of medical ICU patients from the Project IMPACT
database between March 2002 and May 2004 [21]. The
incidence of CDI was 8.4 cases per 1,000 patient-days.
Factors associated with CDI were receipt of clindamycin,
macrolides, older age and female gender. PPI use was
not identified as a significant risk factor. Shaughnessy,
et al. conducted a retrospective cohort study in medical
ICU patients to determine if hospital room assignment
was associated with CDI [22]. In this analysis, prior
room occupant with CDI was significant on multivariate
analysis but neither PPI use nor antibiotic exposure was
linked to CDI. Finally, MacLaren et al. conducted a largeTable 3 Multivariate analysis of confounding variables
associated with Clostridium difficile
Model Covariates included OR (95% CI)* P value
1 Long PPI exposure (2 or more days) 2.19 (1.27 – 3.78) .005
H2RA use 1.12 (0.70 – 1.79) .628
Antibiotic use 2.53 (1.23 – 5.23) .012
Immunosuppression 0.79 (0.51 – 1.23) .297
2 Long PPI exposure (2 or more days) 2.08 (1.26 – 3.43) .004
Antibiotic use 2.53 (1.25 – 5.29) .010
Immunosuppression 0.79 (0.51 – 1.22) .282
3 Long PPI exposure (2 or more days) 2.03 (1.23 – 3.36) .006
Antibiotic use 2.52 (1.23 – 5.18) .012
*Odds ratios adjusted for study duration. OR, odds ratio; CI, confidence interval;
PPI, proton pump inhibitor; H2RA, histamine-2-receptor antagonist.retrospective pharmacoepidemiologic study comparing
GI hemorrhage and infectious complications in ICU
patients who received either PPIs or H2RAs for SUP [9].
After adjusting for propensity score and covariates, the
odds ratio for CDI was significantly higher with PPIs
(OR (95% CI) = 1.29 (1.04 to 1.64)). Similar results were
obtained in a propensity-matched analyses (PPI, 3.4% vs.
H2RA, 2.6%, P = 0.002). This is the first analysis demon-
strating increased risk for CDI with PPIs in ICU patients.
Our results confirm these findings using an alterna-
tive large database of ICU admissions. Future, multi-
center prospective trials are necessary to validate these
conclusions.
PPIs have become the most common agents used for
SUP. One large multicenter study of practice patterns
across the United States and Canada revealed PPIs were
chosen in 70% of patients who received SUP [13]. The
short duration of PPI exposure that is linked to CDI
could have tremendous clinical implications. Clinicians
should investigate strategies to restrict PPI use for indi-
cations such as SUP. The reliance on local, institutional
guidelines to curb practice relative to acid suppressive
therapy appears to have minimal effect [13].
Several limitations are evident when interpreting the
results of our study. First is the utilization of ICD-9
codes to identify outcomes and diagnoses. Limitations to
ICD-9 coding have been previously reported (poor sensi-
tivity, positive predictive value, and so on) [23]. However,
a recent systematic review revealed their diagnostic pre-
dictability to be moderate to strong when used for CDI
and they still remain the primary mechanism to extract
outcomes from large database studies [24]. A second limi-
tation is the case-control design and possibility for bias in
the study groups. We attempted to account for this by
matching patients using three criteria that included age,
Barletta and Sclar Critical Care  (2014) 18:714 Page 6 of 7primary diagnosis and severity of illness. Nevertheless,
some differences could have existed that were not de-
tected. A third limitation is the possibility of confound-
ing variables that were not examined in our multivariate
analysis. Finally, outpatient utilization of PPIs could not
be assessed.
Conclusions
Duration of PPI use is significantly associated with the
acquisition of CDI in critically ill patients. This risk is
most evident when duration of therapy exceeds two or
more days. ICUs should implement measures to restrict
PPI use for indications such as SUP given the unlikelihood
that therapy will be changed before the risk for infectious
complications is apparent. Appropriately powered rando-
mized controlled trials are necessary to confirm these
findings.
Key messages
 Duration of PPI use is significantly associated
with the acquisition of nosocomial Clostridium
difficile-associated diarrhea.
 This risk is evident after only two days of therapy.
 Clinicians should consider alternative forms of acid
suppressive therapy (for example, histamine-2-
receptor antagonists) for indications like stress
ulcer prophylaxis.
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